Skip to main content
Signal8
Catalio Capital Management, LP logo

Catalio Capital Management, LP

CIK: 1958125

Last 13F

Nov 16, 2026

Next 13F

Feb 15, 2027 · in 3mo

13F Portfolio Value

$538.31M

Not total AUM

Holdings (47)

Q3 2026 13F, quarter ended Sep 30, 2026, filed Nov 16, 2026

  • AVALYN PHARMACEUTICALS INC logo
    AVLN

    AVALYN PHARMACEUTICALS INC

    $48.4M

    1.70M sh8.99%+1.4%
  • BRISTOL-MYERS SQUIBB CO logo
    BMY

    BRISTOL-MYERS SQUIBB CO

    $31.18M

    499,716 sh5.79%+21.0%
  • BRIDGEBIO PHARMA INC logo
    BBIO

    BRIDGEBIO PHARMA INC

    $27.97M

    425,111 sh5.20%-6.6%
  • PARABILIS MEDICINES INC logo
    PBLS

    PARABILIS MEDICINES INC

    $26.61M

    824,043 sh4.94%+0.0%
  • JOHNSON & JOHNSON logo
    JNJ

    JOHNSON & JOHNSON

    $26.34M

    99,496 sh4.89%-28.4%
  • ASCENDIS PHARMA A/S logo
    ASND

    ASCENDIS PHARMA A/S

    $23.11M

    101,445 sh4.29%+219.4%
  • ARROWHEAD PHARMACEUTICALS IN logo
    ARWR

    ARROWHEAD PHARMACEUTICALS IN

    $20.63M

    315,247 sh3.83%New
  • SYNDAX PHARMACEUTICALS INC logo
    SNDX

    SYNDAX PHARMACEUTICALS INC

    $19.24M

    1.02M sh3.57%-15.8%
  • DEFINIUM THERAPEUTICS INC logo
    DFTX

    DEFINIUM THERAPEUTICS INC

    $18.95M

    497,964 sh3.52%-11.5%
  • CELCUITY INC logo
    CELC

    CELCUITY INC

    $18.34M

    230,609 sh3.41%New
  • SEPTERNA INC logo
    SEPN

    SEPTERNA INC

    $17.77M

    454,015 sh3.30%-15.3%
  • GUARDANT HEALTH INC logo
    GH

    GUARDANT HEALTH INC

    $16.51M

    92,579 sh3.07%New
  • PROTAGONIST THERAPEUTICS INC logo
    PTGX

    PROTAGONIST THERAPEUTICS INC

    $15.84M

    112,418 sh2.94%+5.3%
  • 10X GENOMICS INC logo
    TXG

    10X GENOMICS INC

    $14.82M

    164,029 sh2.75%New
  • AMYLYX PHARMACEUTICALS INC logo
    AMLX

    AMYLYX PHARMACEUTICALS INC

    $14.72M

    505,882 sh2.73%New
  • MINERALYS THERAPEUTICS INC logo
    MLYS

    MINERALYS THERAPEUTICS INC

    $14.66M

    583,364 sh2.72%-10.1%
  • EDWARDS LIFESCIENCES CORP logo
    EW

    EDWARDS LIFESCIENCES CORP

    $13.91M

    161,121 sh2.58%+29.1%
  • CORVUS PHARMACEUTICALS INC logo
    CRVS

    CORVUS PHARMACEUTICALS INC

    $11.77M

    1.02M sh2.19%-5.5%
  • VERADERMICS INC logo
    MANE

    VERADERMICS INC

    $11.6M

    95,646 sh2.15%+108.6%
  • ENTERA BIO LTD logo
    ENTX

    ENTERA BIO LTD

    $11.41M

    3.92M sh2.12%New
  • DISC MEDICINE INC logo
    IRON

    DISC MEDICINE INC

    $11.31M

    172,709 sh2.10%+8.4%
  • ODYSSEY THERAPEUTICS INC logo
    ODTX

    ODYSSEY THERAPEUTICS INC

    $10.17M

    457,839 sh1.89%+0.0%
  • 4D MOLECULAR THERAPEUTICS IN logo
    FDMT

    4D MOLECULAR THERAPEUTICS IN

    $9.8M

    684,753 sh1.82%+45.3%
  • ULTRAGENYX PHARMACEUTICAL IN logo
    RARE

    ULTRAGENYX PHARMACEUTICAL IN

    $9.04M

    601,760 sh1.68%+90.3%
  • BIOMARIN PHARMACEUTICAL INC logo
    BMRN

    BIOMARIN PHARMACEUTICAL INC

    $8.7M

    144,971 sh1.62%New
  • ANNEXON INC logo
    ANNX

    ANNEXON INC

    $8.4M

    1.99M sh1.56%New
  • RHYTHM PHARMACEUTICALS INC logo
    RYTM

    RHYTHM PHARMACEUTICALS INC

    $8.15M

    85,614 sh1.51%New
  • STRUCTURE THERAPEUTICS INC logo
    GPCR

    STRUCTURE THERAPEUTICS INC

    $8.13M

    260,109 sh1.51%-6.0%
  • NEKTAR THERAPEUTICS logo
    NKTR

    NEKTAR THERAPEUTICS

    $7.68M

    126,817 sh1.43%New
  • IMMUNOCORE HLDGS PLC logo
    IMCR

    IMMUNOCORE HLDGS PLC

    $6.42M

    211,985 sh1.19%+43.2%
  • COGENT BIOSCIENCES INC logo
    COGT

    COGENT BIOSCIENCES INC

    $5.37M

    167,716 sh1.00%New
  • KAILERA THERAPEUTICS INC logo
    KLRA

    KAILERA THERAPEUTICS INC

    $5.35M

    468,750 sh0.99%+0.0%
  • NATERA INC logo
    NTRA

    NATERA INC

    $5.18M

    12,530 sh0.96%-84.8%
  • FRACTYL HEALTH INC logo
    GUTS

    FRACTYL HEALTH INC

    $4.81M

    8.84M sh0.89%+43.3%
  • KARDIGAN INC logo
    KARD

    KARDIGAN INC

    $4.61M

    312,500 sh0.86%+0.0%
  • ELEDON PHARMACEUTICALS INC logo
    ELDN

    ELEDON PHARMACEUTICALS INC

    $4.14M

    1.64M sh0.77%-3.4%
  • HEARTFLOW INC logo
    HTFL

    HEARTFLOW INC

    $3.73M

    74,969 sh0.69%-87.1%
  • BRIDGEBIO ONCOLOGY THERAPEUT logo
    BBOT

    BRIDGEBIO ONCOLOGY THERAPEUT

    $2.87M

    699,532 sh0.53%+119.7%
  • KORSANA BIOSCIENCES INC logo
    KRSA

    KORSANA BIOSCIENCES INC

    $2.81M

    87,702 sh0.52%New
  • FREENOME INC logo
    FRNM

    FREENOME INC

    $2.49M

    158,170 sh0.46%New
  • PROTARA THERAPEUTICS INC logo
    TARA

    PROTARA THERAPEUTICS INC

    $1.56M

    512,287 sh0.29%-1.5%
  • KARYOPHARM THERAPEUTICS INC logo
    KPTI

    KARYOPHARM THERAPEUTICS INC

    $1.19M

    976,191 sh0.22%+3.8%
  • HYPERFINE INC logo
    HYPR

    HYPERFINE INC

    $1.05M

    1.30M sh0.20%-1.3%
  • METAGENOMI THERAPEUTICS INC logo
    MGX

    METAGENOMI THERAPEUTICS INC

    $561K

    528,993 sh0.10%+0.0%
  • FAETH THERAPEUTICS INC logo
    FTH

    FAETH THERAPEUTICS INC

    $438K

    14,718 sh0.08%+0.0%
  • OUTSET MED INC logo
    OM

    OUTSET MED INC

    $322K

    107,456 sh0.06%-9.2%
  • ADARX PHARMACEUTICALS INC logo
    ADRX

    ADARX PHARMACEUTICALS INC

    $226K

    11,357 sh0.04%New

1-47 of 47

Sector Allocation

SEC Filings

FormDescriptionFiled

Catalio Capital Management, LP filed its most recent 13F holdings report, covering Q3 2026 (the quarter ended Sep 30, 2026), on Nov 16, 2026. Its largest reported positions by value are AVLN, BMY, BBIO, PBLS and JNJ. A 13F lists US-listed stock and option positions, not total assets under management.

About Catalio Capital Management, LP

Catalio Capital Management, LP is a Mutual Fund that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 1958125). Signal8 holds 21 13F filings from it. Its SEC filings list New York as its state of incorporation.

Its most recent 13F holdings report covers Q3 2026 (the quarter ended Sep 30, 2026) and was filed on Nov 16, 2026. That report lists 47 securities, not counting options, up from 39 in Q2 2026.

Its five largest reported positions, in order, are AVALYN PHARMACEUTICALS INC (AVLN), BRISTOL-MYERS SQUIBB CO (BMY), BRIDGEBIO PHARMA INC (BBIO), PARABILIS MEDICINES INC (PBLS) and JOHNSON & JOHNSON (JNJ). The next five are ASCENDIS PHARMA A/S (ASND), ARROWHEAD PHARMACEUTICALS IN (ARWR), SYNDAX PHARMACEUTICALS INC (SNDX), DEFINIUM THERAPEUTICS INC (DFTX) and CELCUITY INC (CELC).

Recent 13F filings by Catalio Capital Management, LP

  • Q3 2026: 13F-HR filed Nov 16, 2026, listing 47 securities.
  • Q2 2026: 13F-HR filed Aug 14, 2026, listing 39 securities.
  • Q1 2026: 13F-HR filed May 15, 2026, listing 41 securities.
  • Q4 2025: 13F-HR/A filed Sep 2, 2026, listing 45 securities.
  • Q4 2025: 13F-HR filed Feb 17, 2026, listing 45 securities.
  • Q3 2025: 13F-HR filed Nov 14, 2025, listing 38 securities.

What a Form 13F does and does not show